Inovio Pharmaceuticals Inc (INO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $267.85M
Last updated: Nov 17, 2026 at 11:06 AM ET
Inovio Pharmaceuticals Inc (INO) Earnings: Report Dates and Results
Inovio Pharmaceuticals (INO) is expected to report earnings on Mar 10, 2027. In the quarter ended Sep 30, 2026, Inovio Pharmaceuticals reported EPS of -$0.23, below the -$0.20 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
INO has an expected report date of Mar 10, 2027.
INO Earnings Call
The latest INO earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, INO beat 18 and missed 22. The widest gap in the table came in the quarter ended Jun 30, 2020, when EPS landed 393.07% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.23 | -$0.20 | -$0.20 - -$0.19 | -15.00% | Miss | N/A | 2 | 2 up, 0 down | Nov 10, 2026 | $298901 |
| Jun 30, 2026 | -$0.07 | -$0.25 | -$0.26 - -$0.23 | +72.00% | Beat | N/A | 2 | 2 up, 0 down | Aug 12, 2026 | N/A |
| Mar 31, 2026 | -$0.31 | -$0.33 | -$0.38 - -$0.29 | +6.06% | Beat | N/A | 3 | 2 up, 1 down | May 13, 2026 | N/A |
| Dec 31, 2025 | -$0.28 | -$0.35 | -$0.38 - -$0.28 | +19.59% | Beat | N/A | 4 | 4 up, 0 down | Mar 12, 2026 | N/A |
| Sep 30, 2025 | -$0.87 | -$0.48 | -$0.58 - -$0.40 | -81.25% | Miss | N/A | 5 | 4 up, 1 down | Nov 10, 2025 | N/A |
| Jun 30, 2025 | -$0.61 | -$0.62 | -$0.69 - -$0.53 | +1.61% | Beat | N/A | 5 | 3 up, 0 down | Aug 12, 2025 | N/A |
| Mar 31, 2025 | -$0.51 | -$0.74 | -$0.84 - -$0.65 | +31.08% | Beat | N/A | 4 | 0 up, 1 down | May 13, 2025 | $65343 |
| Dec 31, 2024 | -$0.60 | -$0.83 | -$1.04 - -$0.62 | +27.88% | Beat | N/A | 5 | 2 up, 0 down | Mar 18, 2025 | $116994 |
| Sep 30, 2024 | -$0.89 | -$1.13 | -$1.24 - -$0.94 | +21.24% | Beat | N/A | 6 | 0 up, 0 down | Nov 14, 2024 | N/A |
| Jun 30, 2024 | -$1.19 | -$1.10 | -$1.28 - -$0.94 | -8.18% | Miss | N/A | 6 | 0 up, 0 down | Aug 8, 2024 | $100762 |
| Mar 31, 2024 | -$1.31 | -$0.99 | -$1.17 - -$0.86 | -32.32% | Miss | N/A | 5 | 0 up, 0 down | May 13, 2024 | N/A |
| Dec 31, 2023 | -$1.12 | -$1.27 | -$1.83 - -$0.96 | +11.81% | Beat | N/A | 4 | 0 up, 0 down | Mar 6, 2024 | $102650 |
| Sep 30, 2023 | -$1.56 | -$1.50 | -$1.56 - -$1.44 | -4.00% | Miss | N/A | 3 | 0 up, 0 down | Nov 9, 2023 | $388446 |
| Jun 30, 2023 | -$1.56 | -$1.72 | -$1.92 - -$1.56 | +9.30% | Beat | N/A | 4 | 0 up, 0 down | Aug 9, 2023 | $225971 |
| Mar 31, 2023 | -$1.92 | -$1.80 | -$1.92 - -$1.56 | -6.67% | Miss | N/A | 4 | 0 up, 0 down | May 10, 2023 | $114943 |
| Dec 31, 2022 | -$0.21 | -$0.17 | -$0.19 - -$0.14 | -23.53% | Miss | N/A | 5 | 0 up, 0 down | Mar 1, 2023 | $909061 |
| Sep 30, 2022 | -$1.80 | -$3.27 | -$4.32 - -$2.64 | +44.95% | Beat | N/A | 7 | 0 up, 0 down | Nov 8, 2022 | $9.15M |
| Jun 30, 2022 | -$5.52 | -$3.52 | -$4.44 - -$2.88 | -56.82% | Miss | N/A | 6 | 0 up, 1 down | Aug 9, 2022 | N/A |
| Mar 31, 2022 | -$4.32 | -$3.93 | -$5.88 - -$3.00 | -9.92% | Miss | N/A | 6 | 0 up, 0 down | May 10, 2022 | $199074 |
| Dec 31, 2021 | -$0.50 | -$0.32 | -$0.44 - -$0.17 | -56.25% | Miss | N/A | 9 | N/A | Mar 1, 2022 | $1.22M |
| Sep 30, 2021 | -$3.48 | -$3.62 | -$5.04 - -$2.76 | +3.87% | Beat | N/A | 10 | 3 up, 0 down | Nov 9, 2021 | N/A |
| Jun 30, 2021 | -$4.68 | -$3.06 | -$4.08 - -$2.16 | -52.94% | Miss | N/A | 10 | N/A | Aug 9, 2021 | $272824 |
| Mar 31, 2021 | -$3.24 | -$2.34 | -$2.52 - -$1.92 | -38.46% | Miss | N/A | 7 | N/A | May 10, 2021 | $281556 |
| Dec 31, 2020 | -$0.14 | -$0.22 | -$0.29 - -$0.17 | +36.36% | Beat | N/A | 9 | N/A | Mar 1, 2021 | $5.58M |
| Sep 30, 2020 | -$2.76 | -$2.30 | -$3.12 - -$1.20 | -20.00% | Miss | N/A | 8 | N/A | Nov 9, 2020 | $236178 |
| Jun 30, 2020 | -$9.96 | -$2.02 | -$2.16 - -$1.92 | -393.07% | Miss | N/A | 8 | N/A | Aug 10, 2020 | $267187 |
| Mar 31, 2020 | -$3.12 | -$2.85 | -$3.48 - -$2.16 | -9.47% | Miss | N/A | 6 | N/A | May 11, 2020 | $1.33M |
| Dec 31, 2019 | -$0.38 | -$0.24 | -$0.25 - -$0.23 | -58.33% | Miss | N/A | 6 | N/A | Mar 12, 2020 | $279489 |
| Sep 30, 2019 | -$2.76 | -$3.07 | -$3.60 - -$2.52 | +10.10% | Beat | N/A | 7 | N/A | Nov 12, 2019 | $866863 |
| Jun 30, 2019 | -$3.60 | -$3.46 | -$3.72 - -$2.16 | -4.05% | Miss | N/A | 8 | N/A | Aug 8, 2019 | $135673 |
| Mar 31, 2019 | -$3.60 | -$3.06 | -$3.84 - -$1.68 | -17.65% | Miss | N/A | 8 | N/A | May 9, 2019 | $2.83M |
| Dec 31, 2018 | -$0.35 | -$0.28 | -$0.31 - -$0.21 | -25.00% | Miss | N/A | 5 | N/A | Mar 12, 2019 | $2.50M |
| Sep 30, 2018 | -$3.24 | -$3.54 | -$4.08 - -$2.76 | +8.47% | Beat | N/A | 6 | N/A | Nov 8, 2018 | $2.00M |
| Jun 30, 2018 | -$0.84 | -$2.34 | -$4.32 - -$0.12 | +64.10% | Beat | N/A | 5 | N/A | Aug 7, 2018 | $24.45M |
| Mar 31, 2018 | -$4.32 | -$3.24 | -$3.24 - -$0.24 | -33.33% | Miss | N/A | 5 | N/A | May 9, 2018 | $1.53M |
| Dec 31, 2017 | -$0.23 | -$0.30 | -$0.33 - -$0.26 | +23.33% | Beat | N/A | 5 | N/A | Mar 14, 2018 | $8.79M |
| Sep 30, 2017 | -$4.68 | -$3.05 | -$4.20 - -$1.56 | -53.44% | Miss | N/A | 7 | N/A | Nov 8, 2017 | $2.64M |
| Jun 30, 2017 | -$1.56 | -$2.52 | -$4.20 - -$0.12 | +38.10% | Beat | N/A | 5 | N/A | Aug 8, 2017 | $20.41M |
| Mar 31, 2017 | -$3.72 | -$3.75 | N/A | +0.80% | Beat | N/A | N/A | N/A | May 10, 2017 | $10.38M |
| Dec 31, 2016 | -$0.35 | -$0.30 | N/A | -16.67% | Miss | N/A | N/A | N/A | Mar 15, 2017 | $8.51M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$2.27, after -$3.99 the year before. It was -$8.15 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$2.27 | N/A |
| Dec 31, 2024 | -$3.99 | N/A |
| Dec 31, 2023 | -$6.16 | N/A |
| Dec 31, 2022 | -$11.85 | N/A |
| Dec 31, 2021 | -$11.90 | N/A |
| Dec 31, 2020 | -$15.98 | N/A |
| Dec 31, 2019 | -$10.34 | N/A |
| Dec 31, 2018 | -$8.75 | N/A |
| Dec 31, 2017 | -$10.19 | N/A |
| Dec 31, 2016 | -$8.15 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,700 words across 9 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,701 | 9 | |
| 2026Q2 | Jun 30, 2026 | 3,453 | 8 | |
| 2026Q1 | Mar 31, 2026 | 4,388 | 11 | |
| 2025Q4 | Dec 31, 2025 | 4,386 | 10 | |
| 2025Q3 | Sep 30, 2025 | 4,233 | 9 | |
| 2025Q2 | Jun 30, 2025 | 5,644 | 13 | |
| 2025Q1 | Mar 31, 2025 | 5,027 | 12 | |
| 2024Q4 | Dec 31, 2024 | 7,357 | 11 |
2026Q3 Earnings Call
Opening remarks
Jennie Willson Investor Relations Good afternoon, and thank you for joining the Inovio Third Quarter 2026 Financial Results Conference Call. Joining me on today's call are Dr. Jacqui Shea, President and Chief Executive Officer; Dr. Mike Sumner, Chief Medical Officer; Steven Egge, Chief Commercial Officer; and Peter Kies, Chief Financial Officer. Today's call will review our corporate and financial information for the quarter ended September 30, 2026, as well as provide a general business update. Following prepared remarks, we will conduct a question-and-answer segment. Before we begin, I'd like to remind you that we will be making certain forward-looking statements as outlined in this slide, including, but not limited to, our ability to obtain and maintain regulatory approval of our product candidates; the design and timing of our planned confirmatory study; the potential benefits of VOCERYQ and its potential to become a product preferred by patients and their physicians; our commercial launch plans and strategy, including anticipated cash runway, cash burn and timing of product revenues; and our plans to expand VOCERYQ into additional indications and geographies and advance our broader pipeline. All of these statements are based on the beliefs and expectations of management as of today. Actual events or results could differ materially. We refer you to the documents we file from time to time with the SEC, which, under the heading Risk Factors, identify important factors that could cause actual results to differ materially from those expressed verbally by the company or in this afternoon's press release. This call is being webcast live, and a link can be found on our website, ir.inovio.com. A replay will be made available shortly after this call is concluded. I will now turn the call over to Inovio's President and CEO, Dr. Jacqui Shea.
Jacqueline Shea President and Chief Executive Officer Good afternoon, and thank you to everyone for joining. I'd like to start today's call by highlighting the recent FDA approval of VOCERYQ, formerly known as INO-3107, under the Accelerated Approval Program as a new nonsurgical treatment option to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis, or RRP. In the press release it issued, the FDA stated that VOCERYQ was a groundbreaking therapy and that its approval represented a meaningful scientific breakthrough by offering patients a plasmid DNA-based immunotherapy that harnesses the body's own immune system to fight the underlying cause of RRP. The accelerated approval for VOCERYQ and the broad indication included in its label for adults with RRP are an acknowledgment of the significant unmet need for nonsurgical treatment options for RRP and the potential therapeutic benefit that VOCERYQ can provide.
Frequently Asked Questions About INO
When is Inovio Pharmaceuticals's next earnings date?
Inovio Pharmaceuticals's next earnings report is expected for Mar 10, 2027.
Did INO beat earnings estimates last quarter?
No. Inovio Pharmaceuticals reported EPS of -$0.23 for the quarter ended Sep 30, 2026, below the -$0.20 estimate by 15.00%.
What EPS do analysts expect from INO next quarter?
The consensus EPS estimate for Inovio Pharmaceuticals for the quarter ending Dec 31, 2026 is -$0.20 from 4 analysts, with estimates from -$0.22 to -$0.19.
How often does INO beat earnings estimates?
Inovio Pharmaceuticals beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +7.75%.
INO pages: Overview, Earnings, Forecast, Financials, Competitors